二氯化丙二酰,(苯基亚肼基)- | 19288-90-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 二氯化丙二酰,(苯基亚肼基)-
• 英文名称: 2-(phenylhydrazono)-propanedioyl dichloride
• 英文别名: 2-(phenylhydrazono)propanedioyl dichloride；2-(2-phenylhydrazono)malonyl dichloride；mesoxaloyl dichloride phenylhydrazone；2-phenylhydrazonomalonyl dichloride；(phenylhydrazono)propandioyl dichloride；PhNHN=C(COCl)2；2-(phenylhydrazinylidene)propanedioyl dichloride
• CAS: 19288-90-5
• 化学式: C₉H₆Cl₂N₂O₂
• 分子量: 245.065
• InChiKey: DVARZUUKZACNGW-UHFFFAOYSA-N

物化性质

• 熔点：
  132-135 °C
• 沸点：
  356.0±25.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  二氯化丙二酰,(苯基亚肼基)- 在 四氯化锡 、 硝基苯 作用下， 生成 4-oxo-1,4-dihydrocinnoline-3-carboxylic acid
  参考文献：
  名称：

  552.一种新的cinnoline合成。第一部分。中草酰氯苯hydr的环化反应，生成取代的4-羟基cinnoline-3-羧酸

  摘要：

  DOI：

  10.1039/jr9610002828
• 作为产物：
  描述：

  aniline hydrochloride 在 sodium hydroxide 、 氯化亚砜 、 溶剂黄146 、 sodium nitrite 作用下， 以 乙醇 为溶剂， 反应 17.0h， 生成 二氯化丙二酰,(苯基亚肼基)-
  参考文献：
  名称：

  Solid phase synthesis of 6-acylamino-1-alkyl/aryl-4-oxo-1,4-dihydrocinnoline-3-carboxamides

  摘要：

  6-Acylmino-1-alkyl/aryl-4-oxo-1,4-dihydrocinnoline-3-carboxamides were synthesized in parallel from 6-nitro-4-oxo-1,4-dihydrocinnoline-3-carboxylic acid. The latter formed amides with amines bound to polystyrene-based resins via acid-labile linkers. N1 and N2-alkylation, followed by alkyl migration yielded only N1-alkylated products. Reduction of the 6-nitro group and acylation concluded the synthesis. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2004.06.103

文献信息

• Synthesis and SAR of New 5-Phenyl-3-ureido-1,5-benzodiazepines as Cholecystokinin-B Receptor Antagonists
  作者：Antonella Ursini、Anna M. Capelli、Robin A. E. Carr、Paolo Cassarà、Mauro Corsi、Ornella Curcuruto、Giovanni Curotto、Michele Dal Cin、Silvia Davalli、Daniele Donati、Aldo Feriani、Harry Finch、Gabriella Finizia、Giovanni Gaviraghi、Marc Marien、Giorgio Pentassuglia、Stefano Polinelli、Emiliangelo Ratti、Aldo Reggiani、Giorgio Tarzia、Giovanna Tedesco、Maria E. Tranquillini、David G. Trist、Frank T. M. Van Amsterdam

  DOI：10.1021/jm990967h

  日期：2000.10.1

  A series of 5-phenyl-3-ureidobenzodiazepine-2,4-diones was synthesized and evaluated as cholecystokinin-B (CCK-B) receptor antagonists. Structure-activity relationship (SAR) studies revealed the importance of the N-1 substituent for potent and selective CCK-B affinity. Addition of substituents at the urea side chain provided in some cases more potent compounds. Moreover the introduction of bulky substituents

  合成了一系列5-苯基-3-脲基苯并二氮杂-2，4-二酮，并作为胆囊收缩素-B（CCK-B）受体拮抗剂进行了评估。结构活性关系（SAR）研究表明，N-1取代基对于有效和选择性CCK-B亲和力的重要性。在某些情况下，在脲侧链上添加取代基可提供更有效的化合物。此外，在N-1处引入笨重的取代基（如金刚烷基甲基）和拆分外消旋脲导致了我们的铅化合物GV150013。
• Novel 1,5-Benzodiazepines as CCK-B Ligands. Effect of Aryl-Carbamic Substituents at the C-3 Position Together with Halogen Substitution on the Benzo-Fused Ring
  作者：M. Elvira Tranquillini、Paolo G. Cassarà、Mauro Corsi、Giovanni Curotto、Daniele Donati、Gabriella Finizia、Giorgio Pentassuglia、Stefano Polinelli、Giorgio Tarzia、Antonella Ursini、Franciscus T. M. van Amsterdam

  DOI：10.1002/ardp.19973301107

  日期：——

  The synthesis and biological evaluation as potential CCK‐B receptor ligands of a number of 1‐isopentyl‐3‐aryloxycarbamoyl‐5‐aryl‐1,5‐benzodiazepines substituted with halogen atoms on the benzo‐fused ring is here briefly discussed.

  此处简要讨论了作为潜在 CCK-B 受体配体的许多 1-异戊基-3-芳氧基氨基甲酰基-5-芳基-1,5-苯并二氮杂环上的卤素原子取代的苯二氮卓类药物的合成和生物学评价。
• Use of 1,5-benzo\x9bb!1,4-diazepines to control gastric emptying
  申请人：Glaxo Wellcome Inc.

  公开号：US05910495A1

  公开（公告）日：1999-06-08

  A method of controlling gastric emptying in patients having an early non-insulin-dependent diabetic condition and exhibiting rapid gastric emptying comprising the administration of an effective gastric emptying controlling amount of a compound of Formula (I) ##STR1## or a physiologically acceptable salt or solvate thereof.

  一种控制患有早期非胰岛素依赖型糖尿病病情且胃排空迅速的患者胃排空的方法，包括给予化合物的有效胃排空控制量，该化合物为下式（I）的化合物或其生理上可接受的盐或溶剂。
• [EN] IMMUNOMODULATING HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSES HETEROCYCLIQUES D'IMMUNOMODULATION
  申请人：AVIDEX LTD

  公开号：WO2004081011A1

  公开（公告）日：2004-09-23

  Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R1 and R3 independently represent H; F; CI; Br; -NO2; -CN; C1-C6 alkyl optionally substituted by F or Cl; or C1-C6 alkoxy optionally substituted by F; R4 represents a carboxylic acid group (-COOH) or an ester thereof, or -C(=O)NR6R7, -NR7C(=O)R6, -NR7C(=O)OR6, -NHC(=O)NR7R6 or -NHC(=S)NR7R6 wherein R6 represents H, or a radical of formula - (Alk)m-Q wherein m is 0 or 1, Alk is an optionally substituted divalent straight or branched C1-C12 alkylene, or C2-C12 alkenylene, or C2-C12 alkynylene radical or a divalent C3-C12 carbocyclic radical, any of which radicals may contain one or more -O-, -S- or -N(R8)- links wherein R8 represents H or C1-C4 alkyl, C3-­C4 alkenyl, C3-C4 alkynyl, or C3-C6 cycloalkyl, and Q represents H; -NR9R10 wherein R9 and R10 independently represents H; C1-C4 alkyl; C3-C4 alkenyl; C3-C4 alkynyl; C3-C6 cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or R9 and R10 form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted; and R7 represents H or C1-C6 alkyl; or when taken together with the atom or atoms to which they are attached R6 and R7 form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and X represents a bond or a divalent radical of formula - (Z)n-(Alk)- or - (Alk)-(Z)n- ­wherein Z represents -O-, -S- or -NH-, Alk is as defined in relation to R6 and n is 0 or 1.

  化合物的化学式(I)是CD80的抑制剂，在免疫调节疗法中具有用途：其中R1和R3分别代表H; F; CI; Br; -NO2; -CN; 通过F或Cl取代的C1-C6烷基; 或通过F取代的C1-C6烷氧基; R4代表羧酸基(-COOH)或其酯，或-C(=O)NR6R7，-NR7C(=O)R6，-NR7C(=O)OR6，-NHC(=O)NR7R6或-NHC(=S)NR7R6其中R6代表H，或化学式-(Alk)m-Q的基团，其中m为0或1，Alk是一个可选择取代的直链或支链C1-C12烷基，或C2-C12烯基，或C2-C12炔基基团或双价C3-C12碳环基团，其中任何一个基团可能包含一个或多个-O-，-S-或-N(R8)-键，其中R8代表H或C1-C4烷基，C3-C4烯基，C3-C4炔基，或C3-C6环烷基，而Q代表H; -NR9R10其中R9和R10独立地代表H; C1-C4烷基; C3-C4烯基; C3-C4炔基; C3-C6环烷基; 酯基; 可选择取代的碳环或杂环基团; 或当R9和R10与它们连接的氮一起形成一个环时，该环是可选择取代的; R7代表H或C1-C6烷基; 或当R6和R7与它们连接的原子一起形成一个可选择取代的含有5、6或7个环原子的单环杂环环，X代表一个键或化学式-(Z)n-(Alk)-或-(Alk)-(Z)n-其中Z代表-O-，-S-或-NH-，Alk如R6所定义，n为0或1。
• Novel Benzodiazepine Photoaffinity Probe Stereoselectively Labels a Site Deep within the Membrane-Spanning Domain of the Cholecystokinin Receptor
  作者：Elizabeth M. Hadac、Eric S. Dawson、James W. Darrow、Elizabeth E. Sugg、Terry P. Lybrand、Laurence J. Miller

  DOI：10.1021/jm049072h

  日期：2006.2.1

  representing both antagonist and agonist ligands of the type A cholecystokinin receptor. The parent compounds of the 1,5-benzodiazepine CCK receptor photoaffinity ligands were originally prepared in an effort to develop orally active drugs. The enantiomeric compounds reported in this study selectively photoaffinity-labeled the CCK receptor, resulting in the identification of a site of attachment for the photolabile

  对药物作用的分子基础的理解为改善药物性质和开发作用于相同生物学靶标的更有效和选择性的分子提供了机会。在这项工作中，我们已经确定了结构相关的1,5-苯并二氮杂二苯甲酮衍生物的外消旋混合物中的活性对映体，它们代表A型胆囊收缩素受体的拮抗剂和激动剂配体。1,5-苯并二氮杂pineCCK受体光亲和配体的母体化合物最初是为了开发口服活性药物而制备的。这项研究中报道的对映体化合物选择性地用光亲和标记了CCK受体，从而确定了受体探针深处的拮抗剂探针的光不稳定部分的附着位点。在Leu（88）的跨膜区域，这是跨膜片段2内的残基。相反，激动剂探针标记包括细胞外环一和跨膜片段三的一部分的区域。拮抗剂与受体的共价连接位点在构建拮抗剂-受体复合物的理论三维分子模型中起指导作用。这些模型提供了一种手段，可以在所有当前可利用的生物学数据的背景下可视化物理上合理的配体-受体相互作用，该生物学数据解决了与CCK受体的小分子